OpenAI Acquires Orchestra Bio to Add Drug Development Operations to Its Life Sciences Tools

Google introduced Android Studio Rabbit 2 with support for more than 40 coding agents through the open Agent Client Protocol, including Claude, Codex, and Google Antigravity. Android CLI updates add Compose previews and memory leak analysis for agents. Google also announced an alpha Agentic API powered by Gemini Nano 4, a beta AppFunctions API for shared tool calling, and a Connected Apps Platform preview linking apps to Google Search and Gemini.

OpenAI acquired Orchestra Bio, a startup that helps pharmaceutical teams coordinate drug development, and will integrate it into its Rosalind life sciences platform. Orchestra's agents track trials, flag timeline disruptions such as failed production batches, and suggest next steps. The combined effort aims to connect scientific findings with clinical trials and decisions to get drugs to patients faster; financial terms were not disclosed.

OpenAI announced it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and plans to build on Rosalind, its AI models and tools for life sciences research. Greg Brockman called accelerating drug development an extremely exciting and promising emerging application of OpenAI’s models. https://openai.com/index/openai-to-acquire-orchestra-bio/

OpenAI acquired AI biotech software startup Orchestra Bio on Tuesday for undisclosed terms. Orchestra builds AI agents for drug discovery operations, including tracking finances and resolving clinical trial scheduling issues. OpenAI says Orchestra’s team and technology will contribute to Rosalind, its life sciences research model, and Rosalind Workbench, a tool intended to help researchers plan experiments and analyze results.

Mark Chen welcomed Orchestra Bio and @ashokaraj_ to OpenAI as it broadens its work in AI-assisted drug discovery. In the quoted announcement, OpenAI said it acquired Orchestra Bio, a platform for coordinating drug development, and plans to build on Rosalind, its AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients. https://t.co/56usvittFv

OpenAI announced on October 20 that it acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, with financial terms undisclosed. Its team and technology will join Rosalind, OpenAI’s life sciences AI models and tools. Orchestra uses AI agents to identify disrupted dependencies and timelines and compare responses, leaving decisions to scientists and project leads; continued access for existing customers and an integration timeline were not disclosed.

We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients

OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences research and development. The move is intended to help biopharma teams accelerate drug development and advance new treatments.